ICSID Dismisses Eli Lilly's Claims Against Canada For Patent Invalidation
WASHINGTON, D.C. — A tribunal for the International Centre for Settlement of Investment Disputes (ICSID) on March 20 issued its final award in a dispute over Canadian drug patents, dismissing all...To view the full article, register now.
Already a subscriber? Click here to view full article